Quick Answer
IMMUNIC, INC. reported Research And Development Expense of $81.98 million for the year ending 2025.
- IMMUNIC, INC. showed an increase of +2.4% in Research And Development Expense from 2024 to 2025.
- This data is from IMMUNIC, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), IMMUNIC, INC.'s Research And Development Expense has grown by 1,508.5%.
- Historical annual values: Fiscal year 2025: $81.98 million | Fiscal year 2024: $80.05 million | Fiscal year 2023: $83.22 million | Fiscal year 2022: $71.26 million | Fiscal year 2021: $61.12 million | Fiscal year 2020: $38.64 million | Fiscal year 2019: $22.51 million | Fiscal year 2018: $9.60 million | Fiscal year 2017: $39.34 million | Fiscal year 2016: $30.05 million | Fiscal year 2015: $39.77 million | Fiscal year 2014: $39.48 million | Fiscal year 2013: $21.79 million | Fiscal year 2012: $5.10 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: